Clinical Trials Browser

INDUSTRY × Blastic Plasmacytoid Dendritic Cell Neoplasm × Other hematologic neoplasm × Clear all

NCT04013685 2026-06-02

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1 Recruiting

130 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

96 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Phase 1 Active not recruiting

21 enrolled

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03386513 2024-12-16

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Phase 1/2 Active not recruiting

179 enrolled 1 FDA

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Disorders, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06690827 2024-11-15

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Phase 1 Recruiting

30 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Phase 1/2 Completed

138 enrolled 23 charts 2 FDA

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT05645744 2024-07-22

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Terminated

3 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06006403 2023-08-30

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 1/2 Recruiting

36 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute

NCT02730312 2022-03-08

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Phase 1 Completed

120 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03203369 2019-07-31

ABC123

Phase 1 Terminated

1 enrolled

MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematologic Neoplasms